James Green

James Green is a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Executive Officer of Vogenx, Inc., a clinical stage company focused on therapeutics for GI and metabolic diseases, James has also held leadership roles such as CEO at Avolynt, Inc. and BHV Pharma. James has contributed to the turnaround of Islet Sciences, Inc. as Chairman and CEO and has held positions in investment at Lonza and corporate finance at GlaxoSmithKline Pharma GmbH. In addition to board memberships at Osprey32, Inc. and the Pharmacogenetics for Every Nation Initiative, James has institutional experience at Duke University School of Medicine. Educational credentials include an MBA in Management & Finance from the University of Pittsburgh Katz Graduate School of Business and a BBA from the University of North Florida.